Hypertension Research (2015) 38, 208–212
& 2015 The Japanese Society of Hypertension All rights reserved 0916-9636/15
www.nature.com/hr
ORIGINAL ARTICLE
Higher circulatory level of endothelin-1 in hypertensive
subjects screened through a cross-sectional study of
rural Bangladeshi women
Shamima Akter1,2,3, Subrina Jesmin1,2,3, Yoshio Iwashima4, Sakuramoto Hideaki1, Md Arifur Rahman2,
Md Majedul Islam1,2, Masao Moroi3, Nobutake Shimojo1, Naoto Yamaguchi5, Takashi Miyauchi1,
Satoru Kawano1, Taro Mizutani1 and Yuhei Kawano4
Endothelin-1 (ET-1) is a potential marker of the endothelial dysfunction, which has been shown to be elevated in hypertensive
subjects. No previous study has investigated the circulatory level of ET-1 and hypertension in a South Asian country. The present
study assessed the circulating levels of ET-1 in subjects with or without hypertension and further examined the association of
ET-1 with clinical and metabolic parameters. A total of 2543 rural Bangladeshi women with a mean age of 44.5 years were
studied using a cross-sectional survey. Multiple regressions were used to examine the association between the circulatory ET-1
levels and hypertension. The prevalence of hypertension was 29.3%. The ET-1 levels were significantly higher in the
hypertensive (mean 3.08 pg ml–1, s.e. (0.19)) than in the non-hypertensive subjects (mean 2.01 pg ml–1, s.e. (0.03))
(P = 0.001). After adjusting for age, the ET-1 level had significant positive associations with the diastolic blood pressure
(P = 0.002), systolic blood pressure (P = 0.001), mean arterial pressure (P = 0.002) and fasting blood glucose (P = 0.002). In a
tertile analysis, we found that hypertension in the subjects was significantly increased as the levels of ET-1 increased (P for the
trend = 0.001). In a stepwise multiple regression analysis, after adjusting for age and all other potential variables, we found that
the mean arterial pressure and the fasting plasma levels have significant associations with the ET-1 level. The present study
demonstrates that there is a higher concentration of ET-1 among the hypertensive subjects in an apparently healthy population
of Bangladeshi rural women. The relationship between ET-1 and hypertension requires further investigation to define the clinical
utility and predictive value of serum ET-1 levels for hypertension for a South Asian population.
Hypertension Research (2015) 38, 208–212; doi:10.1038/hr.2014.160; published online 13 November 2014
Keywords: endothelin-1; hypertensive; rural women; South Asian
INTRODUCTION
High blood pressure is an important worldwide public health
challenge because of its high frequency and its concurrent risks of
stroke and cardiovascular and renal diseases.1,2 Worldwide, 26% of the
adult population were hypertensive in 2000, and 29% are projected to
have this condition by 2025.3 In Bangladesh, nearly 39% of the adults
have hypertension, and this figure appears to be higher than among
other South Asian populations.4 The identification of risk factors and
the control of hypertension are of the utmost importance in this
region. The importance of blood pressure as a modifiable risk factor
for cardiovascular disease is well recognized. Although many effective
and inexpensive blood pressure-lowering treatments are available,
other clinical approaches for controlling hypertension need to be
explored.
Endothelin (ET) is a potent endothelial cell-derived venous and
arterial vasoconstrictor peptide5 that consists of a family of 21 amino
acid peptides (ET-1, ET-2 and ET-3).6 Among the family of peptides,
ET-1 is the most abundant isoform and most potent vasoconstrictor in
humans and contributes to the maintenance of the basal vascular
tone.7 In animal models of hypertension, ET-1 is overexpressed in the
vascular wall,8 and mice with an ET-1 gene that has been inactivated
exhibit a slight elevation in blood pressure.9 In addition, ET-1 is
involved in a variety of other physiological processes in both animals
and humans, including cell proliferation,10 fibrosis,11 endothelial
dysfunction,12 arterial stiffness13 and cardiac hypertrophy;14 all of
which may contribute to the development and maintenance of
hypertension. In this context, it is of interest to investigate the
associations between ET-1 and blood pressure in humans.
1
Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; 2Health & Disease Research Center for Rural Peoples (HDRCRP),
Mohammadpur, Dhaka, Bangladesh; 3National Center for Global Health and Medicine (NCGM), Toyama, Shinjuku-ku, Tokyo, Japan; 4National Cerebral and Cardiovascular
Center, Suita City, Osaka, Japan and 5Center for Health Science, Ibaraki Prefectural University, Ami, Ibaraki, Japan
Correspondence: Assistant Professor S Jesmin, Graduate School of Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
E-mail: jsubrina@gmail.com
Received 13 March 2014; revised 20 July 2014; accepted 25 July 2014; published online 13 November 2014
Endothelin-1 and hypertension in Bangladesh
S Akter et al
209
To date, the possible relationship of ET-1 with essential hypertension has been limited to experimental studies,8,15 and few clinical
studies in humans conducted in the developed countries have found
elevated levels of ET-1 among hypertensive subjects,16–20 whereas
other studies have found no significant difference21,22 compared with
the healthy controls. To our knowledge, only one study has
investigated the association between ET-1 and hypertension among
an apparently healthy population.23 Moreover, no previous studies on
this topic have been conducted in South Asian populations or
populations from low-income countries. As racial differences exist in
the plasma levels of ET-1,24 more research addressing the association
between ET-1 and hypertension among other races requires investigation. As such, we aimed to examine the associations between the
circulating ET-1 levels and hypertension among Bangladeshi
rural women.
MATERIALS AND METHODS
Study procedure
The present study is a community-based cross-sectional study performed in
women from rural Bangladesh between 2009 and 2010. A total of 2543 rural
Bangladeshi women with a mean age of 44.5 years were studied using a crosssectional survey. Females aged ⩾ 15 years were selected using the stratified
multistage random sampling method. This sample size was sufficient to test all
of our formulated research hypotheses at the 5% level of significance with a
power of 80% (β = 0.20). We used the World Health Organization’s STEPwise
approach to surveillance (STEPS) approach (modified), which entails a stepwise
collection of the risk factor data based on standardized questionnaires covering
demographic characteristics, somatic illnesses, somatic and mental symptoms,
medications, lifestyle and health-related behaviors (step 1), basic physical
measures (step 2) and basic biochemical investigations, such as blood glucose
and cholesterol (step 3). The women were recruited from the village
communities of the Gaibandha district and Noagon district, covering two of
the divisions of Bangladesh (Rajshahi and Rangpur). (A division is the largest
administrative tier in Bangladesh, and there are a total of seven divisions in
Bangladesh.). The respondents were selected randomly after selecting the
division, district, Upazila and villages and were recruited through local
announcements at the community level and by house-to-house visits. The
details of the study area have been described before in our previous study.25
The participants’ data were obtained through interviews and clinical examinations at mobile examination centers, where blood samples were also collected.
The study was approved by the Ethical Committee of the Health and Disease
Research Center of Rural Peoples, Dhaka, Bangladesh, Shahid Ziaur Rahman
Medical College, Bogra, Bangladesh and conforms to the principles outlined in
the Helsinki Declaration. All of the participants gave their written informed
consent prior to inclusion in the study.
Study subjects
From a total of 2720 recruited women, we excluded the subjects with chronic
illnesses such as hypothyroidism, pregnant women, those on hormone
replacement therapy, those with known illnesses such as ischemic heart disease
and those with diabetes. After the exclusions, a total of 2543 subjects remained
in this study.
Anthropometric and other variables
The anthropometric measurements of these individuals while they were
wearing light clothing and no shoes were obtained by well-trained examiners
as follows: height was measured to the nearest 0.1 cm using a portable
stadiometer (Seca, Hamburg, Germany); weight was then measured in an
upright position to the nearest 0.1 kg using a calibrated balance beam scale;
body mass index was calculated as the body weight (kg) divided by the square
of the body height (m2); and waist circumference measurements were taken at
the end of a normal expiration to the nearest 0.1 cm by measuring from the
narrowest point between the lower borders of the rib cage and the iliac crest.
Blood pressure measurement
Blood pressure was measured twice in the right arm with the subject in a sitting
position using a standard mercury manometer and cuff, to the nearest 2
mm Hg, with the initial reading taken at least 5 min after the subject was made
comfortable, and again after an interval of 15 min. The average systolic and
diastolic blood pressures were then estimated. Hypertension was defined as a
systolic blood pressure ⩾ 140 mm Hg, a diastolic blood pressure ⩾ 90 mm Hg
or the use of antihypertensive medication. The subjects who were determined
to be hypertensive through the initial screening were followed up for 2 months,
with four additional blood pressure measurements.
Biochemical analysis
Blood for the biochemical analysis was obtained from the participants after a
10–12 h overnight fast. The blood sample was collected using the standard
blood sample collection procedure. Immediately after the collection of blood
and labeling the blood vials, the samples were transported to the National
Centre for Global Health and Medicine, Japan, for the biochemical assessment.
For the analysis, the serum was immediately separated from the blood by
centrifugation to evaluate the plasma concentration of the lipids. The
triglycerides levels were measured using the lipoprotein lipase method (Wako
Chemicals, Tokyo, Japan), high-density lipoprotein cholesterol levels were
measured using the Determiner-L kit (Kyowa, Tokyo, Japan) and the fasting
plasma glucose levels were measured using the Hexokinase G-6-PDH kit
(Wako Pure Chemical Industries, Osaka, Japan).
Enzyme-linked immunosorbent assay for plasma ET-1 level
The concentration of the ET-1 in the plasma was determined using a
Quantikine ET-1 Enzyme Immuno Assay Kit (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s protocol. A 4.5 h solid-phase
enzyme-linked immunosorbent assay was used, which contained synthetic ET-1
and antibodies raised against synthetic ET-1. This immunoassay has been
shown to accurately quantitate synthetic and naturally occurring ET-1. The
standards and samples were pipetted into the wells, and if present, the ET-1
antigen was bound by the immobilized antibody. After washing away any
unbound substances, an enzyme-linked monoclonal antibody specific to ET-1
was added to the wells. Following a wash to remove any unbound antibodyenzyme reagent, a substrate solution was added to the wells, and the color
developed in proportion to the amount of ET-1 bound in the initial step. The
color development was then stopped, and its intensity was measured. The ET-1
concentration of each sample was calculated with a standard curve constructed
by plotting the absorbance of each standard solution.
Statistical analysis
The differences in the clinical characteristics between the hypertensive and nonhypertensive subjects were assessed by the t-test and the Mann–Whitney test for
normal and skewed continuous variables, respectively. The mean ± s.e. and the
median (interquartile range) are presented, where appropriate. A linear
regression analysis was used to evaluate the association between the ET-1
plasma levels and the clinical/metabolic parameters for the unadjusted and ageadjusted models. To identify the independent determinants of ET-1 and
hypertension, a stepwise multiple regression analysis was performed in forward
direction with the significance level for additions to the model set to 0.20. The
trend association between the tertiles of the ET-1 levels and the percentage of
subjects with hypertension was tested using linear regression analysis. Receiver
operator characteristic curves and the corresponding area under the curves were
used to evaluate the diagnostic values of the tertiles of the ET-1 for the
hypertensive status. The optimal cut-off point was selected based on the
receiver operator characteristic curves providing the maximum diagnostic
efficiency (the maximum value of specificity % plus sensitivity %). Twosided P values o0.05 were considered statistically significant. All of the analyses
were performed using Stata version 12.0 (Stata Corp, College Station,
TX, USA).
Hypertension Research
Endothelin-1 and hypertension in Bangladesh
S Akter et al
210
RESULTS
The individuals screened in this study as hypertensive were unaware
that they had hypertension. This screening was conducted as part of a
non-communicable disease screening of apparently healthy women in
rural Bangladesh.
Table 1 shows the clinical characteristics of the subjects according to
their hypertensive and non-hypertensive status. The hypertensive
subjects were relatively older, and many of their cardiometabolic
factors, including systolic blood pressure, diastolic blood pressure,
fasting blood glucose, triglycerides levels and waist circumference were
significantly higher than their non-hypertensive counterparts. However, the high-density lipoprotein cholesterol levels were significantly
lower in the hypertensive subjects than in the non-hypertensive
subjects (Po0.05 for all).
The plasma ET-1 levels were significantly higher in the hypertensive
subjects than in the non-hypertensive subjects (P = 0.001) (Figure 1).
Table 2 shows the association between the ET-1 levels and the
metabolic or other clinical parameters. After adjusting for age, the
ET-1 levels were significantly associated with the systolic blood
Table 1 Clinical characteristics of subject according to hypertensive
status
Characteristics
Subjects (prevalence)
Non-hypertensive
Hypertensive
1798 (70.7)
745 (29.3)
P-valuea
40.52 ± 1.34b
48.85 ± 1.21
o0.001
22.67 (20.00–25.00) 22.89 (19.74–25.73)
0.799
Age (years)
BMI (kg m–2)c
Waist circumference (cm)
Triglycerides (mg dl–1)c
75.48 ± 0.75
159.65
81.49 ± 1.03
179.78
HDL cholesterol (mg dl–1)
(100.35–176.96)
42.06 ± 1.36
(128.44–232.01)
36.50 ± 1.45
Systolic blood pressure
(mm Hg)
106.95 ± 1.49
151.57 ± 1.96
o0.001
Diastolic blood pressure
(mm Hg)
71.26 ± 0.79
89.56 ± 1.01
o0.001
MAP (mm Hg)
o0.001
o0.001
0.006
83.18 ± 0.98
110.24 ± 1.21
o0.001
Fasting blood glucose
(mmol l–1)c
6.20 (5.20–6.80)
6.60 (5.60–7.95)
o0.001
Insulin (μU ml–1)c
6.55 (2.66–9.74)
6.70 (3.78–13.64)
0.359
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein, MAP, mean arterial
pressure.
aBased on t-test for normal continuous variables, Mann–Whitney test for non-normal continuous
variables.
bMean ± s.e. for normal variables (all such values.
cMedian (interquartile range) for non-normal variables (all such values).
P=<0.001
Plasma endothelin-1 (pg/ml)
3.5
3.08
3.0
2.5
2.01
2.0
1.5
1.0
0.5
0.0
Non-hypertensive
Hypertensive
Figure 1 Mean levels of plasma endothelin-1 according to hypertensive and
non-hypertensive status.
Hypertension Research
pressure (P = 0.001), diastolic blood pressure (P = 0.002), mean
arterial pressure (MAP) (P = 0.001), fasting plasma glucose level
(P = 0.002) and plasma high-density lipoprotein levels (P = 0.03).
Other variables, including the body mass index, waist circumference,
triglycerides and fasting insulin levels, were not associated with the
ET-1 levels. A stepwise multiple regression analysis considering all of
the variables presented in Table 1 revealed that the mean arterial
pressure and fasting plasma glucose levels were independent determinants of the plasma ET-1 levels (Table 3). In addition, when we
performed multiple logistic regressions for the hypertension status and
the other predictors, we found that an elevated plasma ET-1 level had
a strong association with hypertension (Table 4).
Figure 2 shows the association between the tertiles of the ET-1 levels
and the percentage of hypertension. As shown in the figure,
hypertension was significantly increased in subjects as the levels of
ET-1 increased (P for trend = 0.001).
Figure 3 shows the receiver operator characteristic curve for
hypertension and the tertiles of ET-1. The area under the curves
values were moderately higher (0.758; 95% CI = 0.687–0.829;
s.e. = 0.036; Po0.001), demonstrating the sensitivity and 1-specificity
of the prediction of the hypertension risk for the different levels of
ET-1. The cut-off point for the tertiles of ET-1 was found to be T3, as
the ET-1 levels of T3 were 2.38 or more. The sensitivities and
specificities of ET-1 were 0.563 and 0.866, respectively.
DISCUSSION
In this cross-sectional study of Bangladeshi women, the plasma ET-1
levels were significantly higher in the subjects with hypertension than
in the non-hypertensive subjects, and both the systolic and diastolic
blood pressures were positively associated with ET-1 after adjusting for
age. To our knowledge, this is the first study in an apparently healthy
South Asian population to address the association between the
circulating levels of ET-1 and hypertension.
The elevated ET-1 levels among the subjects with hypertension and
the significant positive association between the ET-1 and the blood
pressure in our study is consistent with some of the previous clinical
studies.16–19 According to these previous studies, the plasma ET-1
levels were significantly higher in the patients with essential hypertension compared with the healthy controls. Moreover, in line with our
study, Seissler et al.26 found a significant positive association between
proET-1 and high blood pressure. However, the findings of our study
were not consistent with a number of other studies. In an apparently
healthy population, Hirai et al.23 found a significant positive association between ET-1 and the systolic and diastolic blood pressures in a
univariate analysis; however, in a multiple stepwise regression model,
both the systolic and diastolic blood pressures were not associated with
ET-1. Similarly, Piatti et al.21 found no significant positive association
of ET-1 with the systolic and diastolic blood pressures in a multiple
regression analysis. Differences in the background characteristics of the
study population may be a potential reason for the inconsistent
findings across the studies. The present findings, together with a
majority of clinical studies, suggest that hypertension may be
associated with elevated ET-1 levels, but more studies from South
Asian countries may clarify the relationship between ET and hypertension that we observed in the present study.
In the present study, we clearly demonstrated through a tertile
analysis that hypertension was significantly increased in subjects as the
levels of ET-1 increased (P for trend = 0.001). Among the hypertensive
subjects who belonged to the highest tertile of the ET-1 level, 50% of
them had a fasting blood glucose level ⩾ 7 mmol l–1, 10% of them
were overweight (body mass index ⩾ 25) and 100% of them had
Endothelin-1 and hypertension in Bangladesh
S Akter et al
211
Table 2 Association between endothelin-1 and others parameters
Unadjusted
Variables
Coefficient (β)
s.e.
Age-adjusted
P-valuea
Coefficient (β)
P-valuea
s.e.
Age (years)
0.0170
0.0077
0.029
BMI (kg m–2)
Waist circumference (cm)
0.0055
0.0202
0.0225
0.0112
0.808
0.074
0.0090
0.0188
0.0223
0.0112
0.689
0.095
Triglycerides (mg dl–1)
HDL cholesterol (mg dl–1)
0.0015
− 0.0213
0.0016
0.0088
0.338
0.017
0.0012
− 0.0193
0.0015
0.0088
0.436
0.030
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
0.0144
0.0294
0.0035
0.0078
o0.001
o0.001
0.0132
0.0265
0.0037
0.0083
o0.001
0.002
MAP (mm Hg)
Fasting blood glucose (mmol l–1)
0.0232
0.0180
0.0056
0.0540
o0.001
0.001
0.0213
0.0168
0.0061
0.0542
0.001
0.002
− 0.0030
0.0060
0.615
−0.0020
0.0059
0.740
Insulin (μU ml–1)
—
—
—
Table 3 Multiple linear regression of plasma levels of endothelin-1
(pg ml–1) and others predictors
Characteristics
MAP (mm Hg)
Fasting blood glucose (mmol l–1)
Coefficient of (β)
s.e.
P-value
0.0251
0.0157
0.0078
0.0617
0.054
0.012
Abbreviation: MAP, mean arterial pressure.
Table 4 Multiple logistic regression of hypertension status and others
predictors
Characteristics
Odds ratio
s.e.
P-value
Percentage of hypertensive subjects
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; MAP, mean arterial pressure.
aBased on the regression analysis.
P for trend < 0.001
80
79.0
60
41.0
40
21.3
20
0
T1 (< 1.99)
T2 (1.99 - 2.38)
T3 (> 2.38)
Tertiles of endothelin-1 (pg/ml)
Age (years)
1.058
0.019
0.004
Waist circumference (cm)
Triglycerides (mg dl–1)
1.147
1.015
0.037
0.004
o0.001
0.001
17.319
0.829
0.001
Endothelin-1 (pg ml–1)
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; MAP, mean arterial
pressure.
nn-Whitney test for non-normal continuous variables.
Mean ± s.e. for normal variables (all such values).
metabolic syndrome (as determined by modified National Cholesterol
Education Program (NCEP) Adult Treatment Panel (ATP) III
criteria). In addition, in the current analysis we found that the fasting
blood glucose level had a positive association with the plasma ET-1
level, as demonstrated through both the univariate and multivariate
regression analyses. Moreover, the plasma high-density lipoprotein
level had a negative significant association with the plasma ET-1 level
only in the univariate regression analysis. Thus, in addition to the
blood pressure, the fasting blood glucose level was also a determinant
for the plasma ET-1 levels in our subjects. However, when we
performed a multiple logistic regression analysis for the hypertensive
status and the other predictors, there was no significant association
between hypertension and the fasting blood glucose level; conversely,
there was a strong association between hypertension and the plasma
ET-1 level in the logistic regression analysis.
Although the mechanisms involved in the induction of ET-1 in
hypertensive subjects remains unclear, several possible explanations
have been suggested. The intravenous infusion of ET causes a rapid
and transient vasodilation followed by a profound and long-lasting
Figure 2 Percentage of subjects with hypertension according to the tertiles
of endothelin-1.
increase in blood pressure.5,27 In vitro experiments have demonstrated
that this increase in blood pressure is related to the profound
vasoconstriction of the resistance arteries of the different vascular
beds of the circulation.28,29 ET-1 not only exerts direct vasoconstrictor
effects but is also able to potentiate other vasoconstrictor substances
such as norepinephrine and serotonin,30 which may be involved in the
development of hypertension.31 Another mechanism may be the
profound renal effects of ET-1.17,23 ET decreases the renal plasma
flow and glomerular filtration rate at a level of the range at which no
generalized alterations in hemodynamics occur.29 As the kidney plays a
central role in the regulation of the chronic hemostasis of the
pressure–volume regulation, these effects may have important roles
for the development of hypertension.
The major strengths of the present study include the use of a large
community-based survey with a relatively large sample size and the
exclusion of subjects with chronic diseases such as heart diseases and
diabetes that may interact with the possible relationship between ET-1
and hypertension. However, the present study also has several
limitations that need to be mentioned. First, the existence of an
association derived from a cross-sectional study does not necessarily
indicate causality. Thus, the present study cannot rule out whether the
higher plasma ET-1 level observed in the present study in hypertensive
subjects is the result of high blood pressure. A prospective cohort
Hypertension Research
Endothelin-1 and hypertension in Bangladesh
S Akter et al
212
Specificity %
100
80
0
20
60
40
20
0
40
60
80
100
100
Sensitivity %
80
60
40
20
0
1 - Specificity %
Figure 3 Receiver operating characteristic for the hypertensive subjects and
the tertiles of endothelin-1.
study design and serial plasma ET-1 measurements are essential to
explore the relationship between the hypertensive status and plasma
ET-1 levels. Second, in assessing the association between ET-1 and
blood pressure, we were unable to adjust for important lifestyle risk
factors, including smoking, alcohol consumption and physical activity.
However, alcohol consumption and smoking are very uncommon
among Bangladeshi women and thus are unlikely to alter the results
after the additional adjustment for these variables.
In conclusion, the findings of our study suggest that the plasma
ET-1 level was elevated among the hypertensive subjects and was
significantly and positively associated with the blood pressure among
the rural women in Bangladesh. Prospective studies are needed to
confirm the present cross-sectional findings among South Asian
subjects.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This work was supported by a Grant-in-Aid for Scientific Research (overseas
academic) from the Ministry of Education, Culture, Sports, Science and
Technology of Japan (23406037, 23406016, 23406029, 24406026 and 25305034)
and the Japan Society for the Promotion of Science. A current project (WDF11610) on gestational diabetes from the World Diabetes Foundation, Denmark to
Health and Disease Research Center of Rural Peoples also supported a part of
this work.
1 He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am
1997; 81: 1077–1097.
2 Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101–106.
3 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of
hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.
4 Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J,
Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail
NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A,
McKee M, Liu L, Mony P, Yusuf S. PURE (Prospective Urban Rural Epidemiology) Study
investigators. Prevalence, awareness, treatment, and control of hypertension in rural
and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310:
959–968.
Hypertension Research
5 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y,
Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature 1988; 332: 411–415.
6 Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human
endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863–2867.
7 Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal
vascular tone. Lancet 1994; 344: 852–854.
8 Khraibi AA, Heublein DM, Knox FG, Burnett JC Jr. Increased plasma level of
endothelin-1 in the Okamoto spontaneously hypertensive rat. Mayo Clin Proc 1993; 68:
42–46.
9 Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T,
Cao WH, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M,
Yazaki Y. Elevated blood pressure and craniofacial abnormalities in mice deficient in
endothelin-1. Nature 1994; 368: 703–710.
10 Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin
stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.
FEBS Lett 1988; 238: 249–252.
11 Dawes KE, Cambrey AD, Campa JS, Bishop JE, McAnulty RJ, Peacock AJ, Laurent GJ.
Changes in collagen metabolism in response to endothelin-1: evidence for fibroblast
heterogeneity. Int J Biochem Cell Biol 1996; 28: 229–238.
12 Faraco G, Moraga A, Moore J, Anrather J, Pickel VM, Iadecola C. Circulating endothelin1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 2013;
62: 759–766.
13 Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor
blockade on cardiac output, aortic pressure, and pulse wave velocity in humans.
Hypertension 2003; 41: 1253–1258.
14 Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z, Franco F, Yanagisawa M. Mice with
cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid
cardiac hypertrophy. Proc Natl Acad Sci USA 2004; 101: 2088–2093.
15 Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T, Fujino M. Plasma
concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt
hypertensive rats. Biochem Biophys Res Commun 1990; 167: 941–947.
16 Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients
with essential hypertension. N Engl J Med 1990; 322: 205.
17 Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F.
Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990;
15: 493–496.
18 Amoroso A, Cossu MF, Mariotti A, Guido F, Ferri GM, De Rosa FG, Sportelli G. Increased
plasma levels of endothelin in patients with essential arterial hypertension. Riv Eur Sci
Med Farmacol 1996; 18: 33–37.
19 Januszewicz A, Lapiński M, Symonides B, Dabrowska E, Kuch-Wocial A, Trzepla E,
Ignatowska-Switalska H, Wocial B, Chodakowska J, Januszewicz W. Elevated
endothelin-1 plasma concentration in patients with essential hypertension. J Cardiovasc
Risk 1994; 1: 81–85.
20 Kohno M, Yasunari K, Murakawa K, Yokokawa K, Horio T, Fukui T, Takeda T. Plasma
immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614–618.
21 Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M, Gernone F, Pontiroli AE.
Relationship between endothelin-1 concentration and metabolic alterations typical of
the insulin resistance syndrome. Metabolism 2000; 49: 748–752.
22 Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper
SJ, Brown MJ. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and
normotensive control subjects. Clin Sci (Lond) 1990; 78: 261–264.
23 Hirai Y, Adachi H, Fujiura Y, Hiratsuka A, Enomoto M, Imaizumi T. Plasma endothelin-1
level is related to renal function and smoking status but not to blood pressure: an
epidemiological study. J Hypertens 2004; 22: 713–718.
24 Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1
concentrations in individuals with essential hypertension. Hypertension 1996; 28:
652–655.
25 Jesmin S, Akter S, Rahman MM, Islam MM, Islam AM, Sultana SN, Mowa CN,
Yamaguchi N, Okazaki O, Satoru K, Kimura S, Hiroe M, Mizutani T, Moroi M. Disruption
of components of vascular endothelial growth factor angiogenic signalling system in
metabolic syndrome. Findings from a study conducted in rural Bangladeshi women.
Thromb Haemost 2013; 109: 696–705.
26 Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, Peters A, Roden M,
Lechner A, Kowall B, Rathmann W. Vasoregulatory peptides pro-endothelin-1 and proadrenomedullin are associated with metabolic syndrome in the population-based KORA
F4 study. Eur J Endocrinol 2012; 167: 847–853.
27 Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in
humans. Reversal by calcium channel blockade but not by nitrovasodilators or
endothelium-derived relaxing factor. Circulation 1991; 83: 469–475.
28 Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries. Intraluminal and
extraluminal dysfunction. Hypertension 1991; 18: 543–549.
29 Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions
of endothelin. J Clin Invest 1989; 83: 317–320.
30 Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, Lüscher TF. Threshold
concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin
in human arteries. A new mechanism of vasospasm? Circulation 1990; 82: 188–195.
31 Echizen H, Freed CR. Altered serotonin and norepinephrine metabolism in rat dorsal
raphe nucleus after drug-induced hypertension. Life Sci 1984; 34: 1581–1589.